XenoGesis and BioAscent forge alliance to offer integrated drug discovery services

XenoGesis and BioAscent forge alliance to offer integrated drug discovery services
May 16, 2018 suecarr

XenoGesis has announced its alliance with BioAscent Discovery Limited to offer integrated drug discovery services.

The alliance brings together two companies from within the BioCity Group, collaborating to deliver medicinal chemistry, biology and DMPK services to clients across the globe.

Both companies have outstanding drug discovery and development credentials. Together they are dedicated to delivering tailored solutions for clients and a more personalised service which ranges from target evaluation through to candidate nomination and predicted clinical pharmacokinetics and dose.

XenoGesis is a fast-growing provider of DMPK services, quantitative bioanalysis, in vitro pharmacology and modelling and simulation for human PK and dose prediction, and the core team has a proven track record of delivery in drug discovery. BioAscent’s integrated drug discovery services are delivered by a team of expert biologists, medicinal chemists and compound management scientists co-located in state-of-the-art biology and chemistry laboratories.

Commenting, Richard Weaver, Managing Director of XenoGesis, said: “Our two businesses are closely aligned and offer great synergies for our clients, to provide a quick and effective route to drug discovery. There are very few organisations that genuinely can provide leading chemistry, biology and DMPK expertise collectively, with a track record of producing a series of viable candidates. Together we will provide a seamless relationship that allows for iterative drug design programmes, whilst reducing costs, improving timelines and increasing success rates for our clients.”

CEO of BioAscent, Paul Smith, added: “BioAscent has recently launched its integrated drug discovery services with a truly exceptional team of medicinal chemists and biologists, building on our established capabilities in compound management and our in-house Compound Cloud library. This strategic alliance with XenoGesis means we can also offer specialist DMPK capabilities and assay evaluation to identify – at the earliest possible stage in the drug discovery process – those compounds that a client can take forward. Together we seek to not just provide our clients with data, but also iterative feedback and advice, right from the start.”

XenoGesis and BioAscent have both received investment from BioCity Group and are based at BioCity Group sites in Nottingham and Glasgow.